Patents by Inventor Andrew Fesler
Andrew Fesler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240011038Abstract: A composition that includes a micro-RNA mimic containing one or more cytosine nucleosides in which at least one cytosine nucleoside is replaced by cytosine arabinoside. Also provided is a method for killing a cancer cell by contacting it with a composition that includes a micro-RNA mimic containing cytosine arabinoside and 5-fluorouracil in which the micro-RNA mimic is miR-15a, miR-16, miR-129, miR-194, miR-192, miR-139, miR-140, or miR-145. Further, disclosed is a method for treating cancer by administering a composition containing a micro-RNA mimic having a guide strand and a passenger strand in which at least one cytosine nucleoside in the guide strand or the passenger strand has been replaced by cytosine arabinoside.Type: ApplicationFiled: June 20, 2023Publication date: January 11, 2024Inventor: Andrew Fesler
-
Publication number: 20230365972Abstract: The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.Type: ApplicationFiled: January 25, 2023Publication date: November 16, 2023Applicant: The Research Foundation for The State University of New YorkInventors: Jingfang Ju, Andrew Fesler
-
Publication number: 20230151363Abstract: The present disclosure provides modified short-interfering ribosomal nucleic acid compositions that have one or more uracil bases replaced a 5-fluorouracil molecule. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within an siRNA nucleotide sequence with a 5-fluorouracil increases the ability of the short interfering RNA to inhibit cancer progression and tumorigenesis when compared to known cancer therapeutics. As such, the present disclosure provides various short-interfering nucleic acid compositions having 5-fluorouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.Type: ApplicationFiled: March 18, 2021Publication date: May 18, 2023Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Jingfang JU, Andrew FESLER
-
Patent number: 11584932Abstract: The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.Type: GrantFiled: October 31, 2018Date of Patent: February 21, 2023Assignee: The Research Foundation for The State University of New YorkInventors: Jingfang Ju, Andrew Fesler
-
Publication number: 20220145304Abstract: The present disclosure provides modified microRNA nucleic acid compositions that have one or more cytosine and/or uracil bases replaced with gemcitabine or a 5-halouracil, respectively. More specifically, the present disclosure reveals that the replacement of cytosine nucleotides within a microRNA nucleotide sequence with a gemcitabine molecule increases the ability of the microRNA to inhibit cancer progression and tumorigenesis. In addition, the present disclosure reveals that the replacement of cytosine nucleotides within a microRNA nucleotide sequence with a gemcitabine molecule and replacement of uracil bases with 5-halouracil increases the ability of the microRNA to inhibit cancer development. As such, the present disclosure provides various modified nucleic acid (e.g., microRNA) compositions having gemcitabine molecules incorporated in their nucleic acid sequences and methods for using the same.Type: ApplicationFiled: March 13, 2020Publication date: May 12, 2022Applicant: The Research Foundation for The State University of New YorkInventors: Jingfang JU, Andrew FESLER
-
Publication number: 20220090076Abstract: The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.Type: ApplicationFiled: November 24, 2021Publication date: March 24, 2022Applicant: The Research Foundation for The State University of New YorkInventors: Jingfang Ju, Andrew Fesler, Younghwa Song, Jun Chung
-
Patent number: 11236337Abstract: The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.Type: GrantFiled: June 26, 2020Date of Patent: February 1, 2022Assignee: The Research Foundation for The State University of New YorkInventors: Jingfang Ju, Andrew Fesler, Younghwa Song, Jun Chung
-
Publication number: 20200354719Abstract: The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.Type: ApplicationFiled: June 26, 2020Publication date: November 12, 2020Applicant: The Research Foundation for The State University of New YorkInventors: Jingfang Ju, Andrew Fesler, Younghwa Song, Jun Chung
-
Publication number: 20190062754Abstract: The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.Type: ApplicationFiled: October 31, 2018Publication date: February 28, 2019Applicant: The Research Foundation for The State University of New YorkInventors: Jingfang Ju, Andrew Fesler